AI Terminal
Alligator Bioscience
Report Publication Announcement • Dec 3, 2025
3138_rns_2025-12-03_10c8aa75-795d-49c1-b60a-f797d19bb340.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
ALLIGATOR BIOSCIENCE PUBLISHES FINANCIAL CALENDAR FOR 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2026:
| Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting |
31 January 2026 |
|---|---|
| Year-end report 2025 | 12 February 2026 |
| Annual report 2025 | March 2026 |
| Interim report Q1 2026 | 5 May 2026 |
| Annual General Meeting | 6 May 2026 |
| Interim report H1 2026 | 27 August 2026 |
| Interim report Q3 2026 | 22 October 2026 |
| Year-end report 2026 | 11 February 2027 |
For further information, please contact:
Søren Bregenholt, CEO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00
Johan Giléus, CFO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00
The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CET on 3 December 2025.
PRESS RELEASE 03 December 2025 08:45:00 CET
About Alligator Bioscience
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.